TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA therapeutics for high-risk and advanced cancers, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who has served as CFO since July 2018 and also served as a director, will continue to provide transition services to ensure a smooth handover. The company has appointed John Tattory as interim CFO, also effective immediately.
Tattory brings over 25 years of financial and operational management experience across the pharmaceutical, medical device, and biotechnology sectors. His career includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies. This deep industry expertise is expected to be invaluable as TransCode continues to advance its pipeline of novel cancer therapies.
The leadership change comes at a critical time for TransCode. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. TransCode also has a portfolio of first-in-class candidates designed to mobilize the immune system to recognize and destroy cancer cells. With Tattory’s financial stewardship, the company aims to maintain momentum in its clinical programs and strategic initiatives.
Investors and stakeholders can stay informed about TransCode’s latest developments through its newsroom at https://nnw.fm/RNAZ. For a full press release, visit https://nnw.fm/8G3ik.
About TransCode Therapeutics: TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
About NetworkNewsWire: NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only). For more information, please visit https://www.NetworkNewsWire.com. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
